Jill Milne
Founder presso ASTRIA THERAPEUTICS, INC.
Patrimonio netto: 61 606 $ in data 31/03/2024
Profilo
Jill C.
Milne is the founder of Astria Therapeutics, Inc., a company founded in 2008.
She currently holds the title of President, Chief Executive Officer & Director at Astria Therapeutics, Inc. Dr. Milne has held former positions at Pfizer Inc. as the Head-Enzyme Target Group.
She also worked at Sirtris Pharmaceuticals, Inc. from 2004 to 2008, where she held the title of Head-Discovery Biology.
Additionally, she worked at Polaris Growth Management LLC as a Principal.
Prior to that, she worked at Pfizer (St. Louis) from 1998 to 2004, where she held the title of Head-Worldwide Drug Pfinder Program.
In terms of education, Dr. Milne holds a doctorate degree from Harvard University and an undergraduate degree from Wellesley College.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
08/02/2024 | 4 377 ( 0.01% ) | 61 606 $ | 31/03/2024 |
Posizioni attive di Jill Milne
Società | Posizione | Inizio |
---|---|---|
ASTRIA THERAPEUTICS, INC. | Founder | 26/06/2008 |
Precedenti posizioni note di Jill Milne
Società | Posizione | Fine |
---|---|---|
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/01/2008 |
Pfizer (St. Louis)
Pfizer (St. Louis) BiotechnologyHealth Technology Part of Pfizer Inc., Pfizer (St. Louis) is a private company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO. | Corporate Officer/Principal | 01/01/2004 |
PFIZER, INC. | Corporate Officer/Principal | - |
Polaris Growth Management LLC
Polaris Growth Management LLC Investment ManagersFinance Polaris Partners is an Independent Venture Capital firm founded in 1996 by Stephen D. Arnold, Jonathan A. Flint and Terrance G. McGuire. Polaris Partners is headquartered in Waltham. | Corporate Officer/Principal | - |
Formazione di Jill Milne
Harvard University | Doctorate Degree |
Wellesley College | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
PFIZER, INC. | Health Technology |
ASTRIA THERAPEUTICS, INC. | Health Technology |
Aziende private | 3 |
---|---|
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | Health Technology |
Polaris Growth Management LLC
Polaris Growth Management LLC Investment ManagersFinance Polaris Partners is an Independent Venture Capital firm founded in 1996 by Stephen D. Arnold, Jonathan A. Flint and Terrance G. McGuire. Polaris Partners is headquartered in Waltham. | Finance |
Pfizer (St. Louis)
Pfizer (St. Louis) BiotechnologyHealth Technology Part of Pfizer Inc., Pfizer (St. Louis) is a private company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO. | Health Technology |
- Borsa valori
- Insiders
- Jill Milne